In contrast, in cases with mutation in KEAP1, some gene clusters demonstrated lower levels of mRNA expression than that in cases with wild-type KEAP1, including immune checkpoint (CD274, CTLA-4, HAVCR2, PDCD1LG2, and VTCN1; Figure 3A); tumor immune microenvironment (IL1B, IL12A, NT5E, PTGS2, TNF; Figure 3B); T-cell effector and IFN-γ-associated signatures (CXCL9, CXCL10, CXCL11, GZMA, GZMB, IFNG, IRF1, PMSB9, and TAP1; Figure 5A); and T-cell receptor (TCR)-related genes (CCL5, CD3G, CD3D, CD4, CD74, GRAP2, IKZF3, IL2RB, LCK, and TIGIT; Figure 5B). This evidence concerns the gene CD3G and neoplasm.